Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Symyoo | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of on-demand therapy with CDFR0812-15/25mg and CDFR0812-15/50mg compared to on-demand therapy with single-drug administration of Clomipramine HCl 15mg in Korean Male Patients Diagnosed with Premature Ejaculation
Clomipramine is a dibenzazepine-derivative tricyclic antidepressant (TCA) and is a potent inhibitor of serotonin and norepinephrine reuptake. Clomipramine may be used in a variety of indications. Condencia Tab contains low dose of 15mg of clomipramine HCl as an active ingredient, which is newly approved to market for the treatment of premature ejaculation. This study is a prospective, randomized, double-blinded, active-control, 3-treatment arm, parallel, multi-center clinical trial. Approximately a total of 297 male patients diagnosed with premature ejaculation will be enrolled and randomized into 3 groups (99 subjects per a group).
The efficacy of oral administration of Clomipramine HCl will be investigated closely compared to the effects after oral administration of CDFR0812-15/25mg and CDFR0812-15/50mg.
The secondary object is to investigate general safety of oral administration of CDFR0812-15/25mg and CDFR0812-15/50mg.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test 1 | Experimental | Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks. |
|
| Test 2 | Experimental | Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks. |
|
| Comparator | Placebo Comparator | Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CDFR0812-15/25mg | Drug | Contains chlomipramine HCl 15mg and sildenafil citrate 25mg. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The fold change of IELT | IELT(Intravaginal Ejaculation Latency Time), which is to be reported through patient diary | From 4 weeks to 8 weeks after dosing |
| Measure | Description | Time Frame |
|---|---|---|
| The % change of IELT | IELT(Intravaginal Ejaculation Latency Time), which is to be reported through patient diary | From 4 weeks to 8 weeks after dosing |
| The mean change of IELT | IELT(Intravaginal Ejaculation Latency Time), which is to be reported through patient diary |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Youngrang Lee | Contact | 82-(0)70-4335-4759 | yrlee@symyoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Hwan-Seok Choi, M.D, Ph.D. | Catholic Medical Center Seoul St. Mary's Hospital | Principal Investigator |
| Sae Woong Kim, M.D., Ph.D. | Catholic Medical Center Seoul St. Mary's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Inje University Ilsan Paik Hospital | Recruiting | Goyang-si | South Korea | |||
| National Health Insurance Service Ilsan Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
| CDFR0812-15/50mg |
| Drug |
Contains chlomipramine HCl 15mg and sildenafil citrate 50mg. |
|
| Condencia | Drug | Contains chlomipramine HCl 15mg. |
|
| CDFR0812-Placebo | Drug | Placebo tablet of CDFR0812. |
|
| Condencia-Placebo | Drug | Placebo tablet of Condencia |
|
| From 4 weeks to 8 weeks after dosing |
| The response rate | PEP (Premature Ejaculation Profile) questionnaire | At 8 weeks after dosing |
| Global impression reported by patient | PGIG (Patient Global Impression of Change in Premature Ejaculation) | At 8 weeks after dosing |
| Administration time of study drug | The time when a patient takes study drug before sexual attempt | for 8 weeks |
| Number of patients with adverse events | It will be assessed by CTCAE v4.03 | for 8 weeks |
| Recruiting |
| Goyang-si |
| South Korea |
| Pusan National University Hospital | Recruiting | Pusan | South Korea |
| Catholic Medical Center Seoul St. Mary's Hospital | Recruiting | Seoul | South Korea |
| Ewha Womans University Medical Center | Recruiting | Seoul | South Korea |
| Korea University Guro Hospital | Recruiting | Seoul | South Korea |
| Samsung Medical Center | Recruiting | Seoul | South Korea |
| Seoul National University Hospital | Recruiting | Seoul | South Korea |
| Catholic university of Korea Uijeongbu St.Mary's Hospital | Not yet recruiting | Uijeongbu-si | South Korea |
| ID | Term |
|---|---|
| D061686 | Premature Ejaculation |
| ID | Term |
|---|---|
| D000097910 | Ejaculatory Dysfunction |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D012735 | Sexual Dysfunction, Physiological |
| D052801 | Male Urogenital Diseases |
| D020018 | Sexual Dysfunctions, Psychological |
| D001523 | Mental Disorders |
Not provided
Not provided